Market Intelligence, Clinical Progress, and High-Purity Reagents for Immuno-Oncology Development targeting the Nectin Axis.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PVRIG drug discovery.
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PVRIG ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View PVRIG Products |
| Gene Delivery | PVRIG Promise-ORF / Lentivirus Full-length ORF for stable cell line construction. Ideal for Flow Cytometry/Cell-based assays. |
View PVRIG Products |
| Benchmark Ab | Anti-PVRIG (Sequence of COM-701) Recombinant positive control for binding inhibition assays. |
View PVRIG Products |
| Validator | PVRIG siRNA Set For knockdown verification and specificity controls. |
View PVRIG Products |
| Ligand Partner | NECTIN2 (PVRL2/CD112) ECD-Fc High-purity ligand for blocking assays and SPR validation. |
View NECTIN2 Products |
| Competing Receptor | TIGIT Checkpoint receptor sharing functional axis. For combination therapy screening. |
View TIGIT Products |
| Co-receptor | CD226 (DNAM-1) Competing receptor for NECTIN2 binding. Counter-screening essential. |
View CD226 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse/human evaluation | Human/Mouse/Cyno ortholog PVRIG proteins available with >95% purity, Sequence Verified |
| Nectin family selectivity (vs. NECTIN1/3) | PVRIG-specific epitope mapping supported by verified NECTIN2 and control proteins |
| Ligand blocking & competition assay | High-purity NECTIN2 (PVRL2) ECD-Fc included for competitive ELISA/SPR assays |
| Cell surface conformation validation | Lentivirus Premade Particles for stable PVRIG-expressing lines (Flow Cytometry ready) |
| Lack of positive controls | Clinical Benchmark Antibodies (COM-701 sequence biosimilar) included |
| Off-target false positives | Validated siRNA and homolog panel (TIGIT, CD96, DNAM-1) for specificity checks |
Live PVRIG R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Mechanism Research
- ➤ Latest Resistance Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for PVRIG therapeutics is intensifying, with Compugen (in collaboration with Gilead) leading clinical evaluation with COM-701, and multiple biotechs advancing combination strategies. As first-generation monotherapies establish safety profiles, the next wave of R&D is targeting the rational combination with TIGIT, PD-1, and DNAM-1 axis modulators to overcome cold tumor microenvironments. The dominant modality remains blocking monoclonal antibodies, though bispecific constructs (PVRIG/TIGIT) are entering preclinical development. Additionally, cell therapy (CAR-T) targeting PVRIG is being explored in preclinical stages for refractory cancers.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Blocking mAb | Compugen (Gilead), Compass Therapeutics | Solid Tumors (NSCLC, Ovarian, Endometrial) | Blocking ELISA (Need PVRIG + NECTIN2 pair), Species cross-reactivity |
| Bispecific Antibody | Emerging Biotechs | Advanced Solid Tumors | Heterodimer validation, Dual-target binding assays (PVRIG/TIGIT) |
| Combination Therapy | BioNTech (collaborations) | Anti-PD-1 refractory | Multi-target panel screening (PVRIG/TIGIT/PD-1) |
| Cell Therapy (CAR-T) | Preclinical stage | Refractory Cancers | Target expression profiling (Need validated Flow Cytometry Abs) |
Molecular Differentiation & Assay Strategy
Developing best-in-class PVRIG therapeutics requires addressing key differentiation criteria:
- Affinity & Blocking: High affinity to competitively block PVRIG-NECTIN2 interaction without interfering with DNAM-1 binding. Assay recommendation: SPR/BLI affinity measurement; flow cytometry-based competitive binding assay.
- Selectivity & Cross-reactivity: Ensure no off-target binding to homologous nectin family members (TIGIT, CD96, PVR). Need cynomolgus cross-reactivity for toxicology. Assay recommendation: Nectin-family off-target panel; cross-species SPR comparison.
- Internalization & Delivery: For ADC development, assess internalization efficiency; for standard antibodies, optimize for solid tumor penetration (moderate affinity may be superior). High-concentration stability testing recommended.
- Fc Engineering: Avoid ADCC/CDC to prevent depletion of effector cells (use IgG4 or Fc mutations). Assay recommendation: FcγR binding validation using high-purity Fc receptor proteins.
TarMart provides sequence-verified, high-purity (>95%) PVRIG ECD-Fc protein (HEK293 expressed) and clinical benchmark antibodies (COM-701 sequence) to accelerate your candidate screening.
Key Genetic Variation
A coding variant in PVRIG, dbSNP rs2906645 (UniProt VAR_043624), has been identified. This single nucleotide polymorphism may affect the protein's immunoglobulin domain structure or ligand binding affinity, though functional validation is still ongoing. Researchers should consider this variant when designing assays and interpreting preclinical data.
Conclusion
PVRIG represents a promising next-generation immune checkpoint target within the DNAM-1 axis. TarMart's comprehensive toolkit—covering antigens, gene delivery, benchmark antibodies, and related pathway proteins—enables robust preclinical development from target validation to lead optimization.